Issue Date: October 27, 2014
NewLink, Genentech Hook Up
Immunotherapeutics specialist NewLink Genetics has licensed NLG919, its indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to Genentech. NewLink will receive $150 million up front and is eligible to receive milestone payments and royalties. Genentech also will fund future R&D and manufacturing. IDO pathway inhibitors are small-molecule immune checkpoint inhibitors that can complement Genentech antibodies being developed as immunotherapies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society